Regentis Develops Solvent-Free GelrinC Process Boost
HERZLIYA, Israel, March 17, 2026 Regentis Biomaterials Ltd. has announced a breakthrough solvent-free manufacturing process for its lead regenerative...
Alzheimer’s Disease ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy Healthcare Innovation Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody NSCLC Oncology oncology innovation oncology research Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
HERZLIYA, Israel, March 17, 2026 Regentis Biomaterials Ltd. has announced a breakthrough solvent-free manufacturing process for its lead regenerative...
HERZLIYA, Israel, January 29, 2026 — Regentis Biomaterials Ltd. announced a significant expansion of its U.S. clinical site network...
Irvine, California | December 30, 2025 — Overture Orthopaedics, a U.S.-based medical device company specializing in joint preservation technologies,...
